225 related articles for article (PubMed ID: 16289523)
21. The politics of place(ment): problematising the provision of hepatitis C treatment within opiate substitution clinics.
Rance J; Newland J; Hopwood M; Treloar C
Soc Sci Med; 2012 Jan; 74(2):245-53. PubMed ID: 22133583
[TBL] [Abstract][Full Text] [Related]
22. The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004.
Holtzman D; Barry V; Ouellet LJ; Des Jarlais DC; Vlahov D; Golub ET; Hudson SM; Garfein RS
Prev Med; 2009 Aug; 49(1):68-73. PubMed ID: 19410600
[TBL] [Abstract][Full Text] [Related]
23. Gender differences in the impact of comprehensive services in substance abuse treatment.
Marsh JC; Cao D; D'Aunno T
J Subst Abuse Treat; 2004 Dec; 27(4):289-300. PubMed ID: 15610830
[TBL] [Abstract][Full Text] [Related]
24. Treatment for substance abuse in Australia: a comparison of public and private programs.
McNeese-Smith DK
Int J Psychiatr Nurs Res; 2003 Sep; 9(1):1025-38. PubMed ID: 14533233
[TBL] [Abstract][Full Text] [Related]
25. Integrating HCV services for drug users: a model to improve engagement and outcomes.
Sylvestre DL; Zweben JE
Int J Drug Policy; 2007 Oct; 18(5):406-10. PubMed ID: 17854729
[TBL] [Abstract][Full Text] [Related]
26. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia.
Vicknasingam B; Narayanan S; Navaratnam V
Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801
[TBL] [Abstract][Full Text] [Related]
27. A nationwide survey of hepatitis C services provided by drug treatment programs.
Strauss SM; Falkin GP; Vassilev Z; Des Jarlais DC; Astone J
J Subst Abuse Treat; 2002 Mar; 22(2):55-62. PubMed ID: 11932130
[TBL] [Abstract][Full Text] [Related]
28. Factors associated with exposure to hepatitis B virus in injection drug users.
Backmund M; Meyer K; Schuetz C; Reimer J
Drug Alcohol Depend; 2006 Sep; 84(2):154-9. PubMed ID: 16481128
[TBL] [Abstract][Full Text] [Related]
29. Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services.
Strauss SM; Astone-Twerell J; Munoz-Plaza CE; Des Jarlais DC; Gwadz M; Hagan H; Osborne A; Rosenblum A
BMC Health Serv Res; 2007 Mar; 7():39. PubMed ID: 17346346
[TBL] [Abstract][Full Text] [Related]
30. Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment.
Watson B; Conigrave KM; Wallace C; Whitfield JB; Wurst F; Haber PS
Drug Alcohol Rev; 2007 May; 26(3):231-9. PubMed ID: 17454012
[TBL] [Abstract][Full Text] [Related]
31. Injection drug users and the provision of hepatitis C-related services in a nationwide sample of drug treatment programs.
Vassilev ZP; Strauss SM; Astone J; Des Jarlais DC
J Behav Health Serv Res; 2004; 31(2):208-16. PubMed ID: 15255228
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis C virus reinfection in injection drug users.
Grebely J; Conway B; Raffa JD; Lai C; Krajden M; Tyndall MW
Hepatology; 2006 Nov; 44(5):1139-45. PubMed ID: 17058216
[TBL] [Abstract][Full Text] [Related]
33. The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection.
Hopwood M; Treloar C
Int J Drug Policy; 2007 Oct; 18(5):374-80. PubMed ID: 17854725
[TBL] [Abstract][Full Text] [Related]
34. Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reduction.
Hallinan R; Byrne A; Dore GJ
Drug Alcohol Rev; 2007 Jul; 26(4):437-43. PubMed ID: 17564882
[TBL] [Abstract][Full Text] [Related]
35. High-frequency users of detoxification: who are they?
Amodeo M; Lundgren L; Chassler D; Witas J
Subst Use Misuse; 2008; 43(7):839-49. PubMed ID: 18570019
[TBL] [Abstract][Full Text] [Related]
36. On-site medical care in methadone maintenance: associations with health care use and expenditures.
Gourevitch MN; Chatterji P; Deb N; Schoenbaum EE; Turner BJ
J Subst Abuse Treat; 2007 Mar; 32(2):143-51. PubMed ID: 17306723
[TBL] [Abstract][Full Text] [Related]
37. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.
Sutton AJ; Gay NJ; Edmunds WJ; Hope VD; Gill ON; Hickman M
BMC Infect Dis; 2006 Jun; 6():93. PubMed ID: 16762050
[TBL] [Abstract][Full Text] [Related]
38. Patterns of drug use and associated harms among rural injecting drug users: comparisons with metropolitan injecting drug users.
Day C; Conroy E; Lowe J; Page J; Dolan K
Aust J Rural Health; 2006 Jun; 14(3):120-5. PubMed ID: 16706881
[TBL] [Abstract][Full Text] [Related]
39. Molecular epidemiology of HCV monoinfection and HIV/HCV coinfection in injection drug users in Liuzhou, Southern China.
Tan Y; Wei QH; Chen LJ; Chan PC; Lai WS; He ML; Kung HF; Lee SS
PLoS One; 2008; 3(10):e3608. PubMed ID: 18974888
[TBL] [Abstract][Full Text] [Related]
40. Urban U.S. hospitals and the mission to provide HIV-related services: changes and correlates.
White KR; Roggenkamp SD; LeBlanc AJ
J Healthc Manag; 2002; 47(1):27-39; discussion 39-40. PubMed ID: 11836964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
